QQ客服 官方微博 反馈留言

	Entecavir vs lamivudine therapy for na?ve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure
	Yang Zhang[1,2]; Xiao-Yu Hu[1,2]; Sen Zhong[1]; Fang Yang[2]; Tao-You Zhou[3]; Guo Chen[1]; Yan-Yan Wang[1]; Jian-Xing Luo[2]
	2014
卷号	0期号:16页码:4745-4752
关键词	Acute-on-chronic liver failure Hepatitis B Entecav
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4338146
专题	成都中医药大学
作者单位	1.[1]Department of Infectious Diseases, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China 2.[2]Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China 3.[3]Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
推荐引用方式 GB/T 7714	Yang Zhang[1,2],Xiao-Yu Hu[1,2],Sen Zhong[1],et al. Entecavir vs lamivudine therapy for na?ve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure[J],2014,0(16):4745-4752.
APA	Yang Zhang[1,2].,Xiao-Yu Hu[1,2].,Sen Zhong[1].,Fang Yang[2].,Tao-You Zhou[3].,...&Jian-Xing Luo[2].(2014).Entecavir vs lamivudine therapy for na?ve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.,0(16),4745-4752.
MLA	Yang Zhang[1,2],et al."Entecavir vs lamivudine therapy for na?ve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure".0.16(2014):4745-4752.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。